Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
HAE · NYSE · Health Care Supplies
Haemonetics (HAE) · oqro.io/stocks/HAE · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$120.37−2.49 (−2.03%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
No open-market purchase by an insider of Haemonetics was filed in the last 90 days. The latest on record was on Nov 12, 2025.
Since 2005, Haemonetics insiders reported 142 open-market purchases and 715 sales on Forms 4 and 5, with purchases in 12 different years, most recently 2025.
In the last 90 days, 1 insider of Haemonetics (HAE) reported 1 open-market sale worth $101K in total on SEC Form 4. The largest seller by value was Farris Maryanne Maunsell, with $101K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Haemonetics (HAE) was disclosed by a member of Congress in the last 12 months.
Haemonetics's next results are expected on Feb 3, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+60.1% (+$45.18) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $75.19 on Nov 19, 2025 to $120.37 on Nov 19, 2026 (+60.1%). Disclosed in this range: 0 insider trades, 1 pre-arranged insider sale, 0 Congress trades, and 21 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Supplies company based in Boston, Massachusetts.
Last 12 months
+60.1%
Market value
$5.48B
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.6M shares sold short (7.9% of shares outstanding), +5.0% vs the previous count, 6.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue, fiscal 2026
$1.33B
−2.0% vs the year before
Net income, fiscal 2026
$97.3M
As reported in the annual filing
Shares outstanding
45.5M
As of Oct 30, 2026
In fiscal 2026 the company spent $175M buying back its own shares. Cash actually paid, from its cash-flow statement.
New federal contracts from the last 12 months add up to 0.03% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Farris Maryanne Maunsell (VP, Chief Accounting Officer) sold ~$101K of Haemonetics
Automatic saleMaunsell Farris Maryanne (Officer) plans to sell ~$101K of Haemonetics
Planned, from payFederal contracts
Vascade MVP.
The Defense Department has committed $84K to Haemonetics so far. It runs until Jun 2, 2026.
Federal contracts
Express report: nx orders placed during the month of august, 2026
The Department of Veterans Affairs has committed $27K to Haemonetics so far. It runs until Aug 31, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$358M
+9.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$298M
This quarter $113M, a year earlier $106M
Net debt
$876M
Debt $1.14B, cash $261M, at Sep 26, 2026
Backlog
$30.1M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
People read Haemonetics's Wikipedia article about 14 times a day over the last week, close to the 15 on a usual day of the three months before.
May 15, 2026Busiest day: 48 views on Oct 8, 2026Nov 20, 2026
Views of the article Haemonetics, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Fails to deliver: 13K shares (about $1.61M) were not delivered on time for settlement on Oct 16, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 46.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (29.6% on ATS, 16.6% with other brokers), close to its 26-week average of 46.0%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (13.5%), SIGMA X2 (12.7%), INTELLIGENT CROSS LLC (11.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
No Schedule 13D or 13G filing on HAE over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
0 certified in FY2026 Q3, vs 1 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Against the S&P 500 over the year
Insiders of Haemonetics reported 142 open-market purchases and 715 sales since 2005; purchases in 12 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $101K1×1 trade |
| 2025 | $99K1×1 trade | — |
| 2024 | — | $3.46M15×15 trades |
| 2023 | — |
Since Nov 18, 2025, HAE is up 61.8% and the index fund is up 8.5%: 53 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much HAE moves
Beta 0.3 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
| 2022 | — | $4.95M28×28 trades |
| 2021 | — | $6.31M37×37 trades |
| 2020 | $324K1×1 trade | $13.1M48×48 trades |
| 2019 | — | $33.5M62×62 trades |
| 2018 | — | $12.1M33×33 trades |
| 2017 | — | $6.19M122×122 trades |
| 2016 | $2.1M1×1 trade | $909K23×23 trades |
| 2015 | — | $8.62M42×42 trades |
| 2014 | — | $7.45M38×38 trades |
| 2013 | $106K7×7 trades | $17.7M48×48 trades |
| 2012 | $151K11×11 trades | $30.4M74×74 trades |
| 2011 | $132K11×11 trades | $6.36M24×24 trades |
| 2010 | $160K16×16 trades | $26.7M25×25 trades |
| 2009 | $395K14×14 trades | $9.58M21×21 trades |
| 2008 | $539K20×20 trades | $23.6M26×26 trades |
| 2007 | $163K14×14 trades | $4.52M13×13 trades |
| 2006 | $5.13M45×45 trades | $11M28×28 trades |
| 2005 | $49K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
The three months Jun 28, 2026 to Sep 26, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
+13% on the same quarter a year earlier ($182M). Operating income $62.4M, a 30% margin
+5.1% on the same quarter a year earlier ($145M). Operating income $31.7M, a 21% margin
+12% on the same quarter a year earlier ($240M)
+8.5% on the same quarter a year earlier ($43M)
+4.9% on the same quarter a year earlier ($22.6M)
−11% on the same quarter a year earlier ($18M)
−2.6% on the same quarter a year earlier ($3.68M)
Fiscal year Mar 30, 2025 to Mar 28, 2026, from the annual report filed May 20, 2026. Read the filing
+4.3% on the year before ($564M). Operating income $104M, a 18% margin
−2.0% on the year before ($535M). Operating income $185M, a 35% margin
−15% on the year before ($261M). Operating income $50M, a 23% margin
−2.8% on the year before ($1.01B)
+5.3% on the year before ($176M)
−5.5% on the year before ($92.3M)
+9.3% on the year before ($62.4M)
−42% on the year before ($19.5M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, “Plasma” includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed May 20, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed May 20, 2026, compared with the one filed May 21, 2025. Read the filing
Information with respect to this Item may be found in Note 15, Commitments & Contingencies, within the consolidated financial statements in Item 8 of this Annual Report on Form 10-K, which is incorporated herein by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed May 20, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 3, 2027
Purchases after results
Not enough history
From Haemonetics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Haemonetics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.